ADC Capacity Updates

  1. Catalent Capabilities Update September 2026: ADC 9/21/2026

    Discover how a single, consistent analytical partner can simplify your path to IND and BLA — no matter where you manufacture.

  2. Lonza Capabilities Update September 2026: ADC 9/18/2026

    Iwan Bertholjotti, Sr. Director of Commercial Development for Bioconjugates, discusses how Lonza's capabilities meet the growing demand for seamless progression from clinical development to commercial manufacturing.

  3. Avid Bioservices Capabilities Update September 2026: ADC 9/15/2026

    Speed biologics programs from development to commercialization using standardized platforms, single-use technologies, and integrated manufacturing to minimize risk and strengthen supply.

  4. Lotte Biologics Capabilities Update September 2026: ADC 9/14/2026

    Advanced bioconjugates require specialized chemistry, containment, and process control. Tailored conjugation strategies and expert support streamline development and accelerate high-quality therapeutics.

  5. Samsung Biologics Capabilities Update June 2026: ADC 6/19/2026

    Explore how our integrated bioconjugation platform and expanded capabilities can help advance the development and scalable manufacturing of next-generation therapeutics.

  6. Lonza Advanced Synthesis Capabilities Update June 2026: ADC 6/19/2026

    Uncover how integrated late-phase bioconjugate capabilities and scalable manufacturing strategies are helping to address the challenges of emerging modalities as they progress toward commercial production.

  7. Simtra BioPharma Solutions June 2026 Capabilities Update: ADC 6/19/2026

    Coordinate expertise across development, manufacturing, and testing to streamline ADC workflows, cut handoffs, and accelerate timelines — moving teams from early development to commercialization. 

  8. Simplifying ADC Development Through CDMO Collaboration 6/17/2026

    Two CDMOs are working together to simplify ADC development. Learn how integrated support and collaboration can reduce complexity, streamline transfers, and keep programs moving forward.

  9. Abzena Capabilities Update June 2026: ADC 6/16/2026

    Antibody-Oligonucleotide Conjugates expand targeted gene modulation. Overcoming manufacturing, annealing, and loading-ratio challenges requires advanced bioconjugation and robust orthogonal analytics.

  10. Abzena Capacity Update October 2025: ADC 10/15/2025

    Explore ThioBridge™ as an efficient site-specific conjugation technology to generate ADCs and other conjugate modalities, such as AOCs and conjugates for diagnostic applications.